AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03808610
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03808610
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01600014
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
Trial: NCT03591133
Drug: TS-143
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03591133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03333343
Drug: EGF816
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT04524273
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV placebo matched to inebilizumab
Trial: NCT04539496
Drug: XZP-3287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 20-560 mg QD, oral~* 240-480 mg BID, oral
Trial: NCT04539496
Drug: XZP-3287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg BID, oral
Trial: NCT00018694
Drug: Chenodeoxycholic Acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005089
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
Trial: NCT00005089
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
Trial: NCT02647125
Drug: Huachansu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
Trial: NCT00354627
Drug: TMC125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg b.i.d. till commercially available.
Trial: NCT00596414
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02365649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Dosing
Trial: NCT02365649
Drug: ABT-494
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Dosing
Trial: NCT02226367
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study drug arm placebo
Trial: NCT00554840
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
Trial: NCT04398771
Drug: Rosuvastatin/Valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovatitan QD for 12 weeks
Trial: NCT02769689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
Trial: NCT02769689
Drug: fingolimob (FTY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
Trial: NCT04647708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to M5049.
Trial: NCT00087685
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg by mouth Daily
Trial: NCT02400359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
Trial: NCT01000623
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04789005
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
Trial: NCT04421105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02028806
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Trial: NCT02243189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single nasal dose of placebo matching to JNJ-43260295 will be given.
Trial: NCT00758420
Drug: Agitated Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
Trial: NCT04299373
Drug: Alcohol: Oral administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who plan to undergo bariatric surgery will consume a controlled dose of alcohol orally.
Trial: NCT04299373
Drug: Alcohol: Intravenous administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who plan to undergo bariatric surgery will be infused with alcohol intravenously.
Trial: NCT01551381
Drug: EV-077
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily oral administration
Trial: NCT01551381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily oral administration
Trial: NCT03044730
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04770701
Drug: Ahah Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months.
Trial: NCT00887601
Drug: MK3134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
Trial: NCT00887601
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules only in one of the four treatment periods.
Trial: NCT04104321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID
Trial: NCT00887601
Drug: MK3134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
Trial: NCT04169126
Drug: F-18 PMPBB3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
Trial: NCT01917058
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01280006
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Indomethacin: 50 mg, Oral, three times per day for five days.
Trial: NCT01280006
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses.
Trial: NCT01280006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Placebo: Oral, three times per day for five days.
Trial: NCT03269526
Drug: EGFR BATs after standard of care chemo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
Trial: NCT03107481
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1g IV
Trial: NCT02441387
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
Trial: NCT03009058
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care chemotherapy
Trial: NCT03009058
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care chemotherapy
Trial: NCT03009058
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care chemotherapy
Trial: NCT03596502
Drug: Direct oral anticoagulants (DOACs)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
Trial: NCT00711698
Drug: nurse-administered intermittent IV bolus opioid therapy (NAIBOD)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm patients will receive the current standard of care of IV bolus narcotic therapy
Trial: NCT01535040
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth through completion of 12 weeks.
Trial: NCT02059174
Drug: MK-1293
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1293 0.4 units/kg administered subcutaneously
Trial: NCT02059174
Drug: EU-Lantus™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU-Lantus™ 0.4 units/kg administered subcutaneously
Trial: NCT02059174
Drug: Novolog™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
Trial: NCT01651728
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet 20 mg once daily for 30 days
Trial: NCT01651728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily for 30 days
Trial: NCT00540787
Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
Trial: NCT02632760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo - no active drug
Trial: NCT01901159
Drug: RO4995819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of RO4995819 (tablet)
Trial: NCT00712764
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01901159
Drug: RO4995819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of RO4995819 (capsule)
Trial: NCT00712764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00756223
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation Arm A (4 weeks)
Trial: NCT00756223
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation Arm B (3 weeks)
Trial: NCT01736176
Drug: Levodopa-Carbidopa Intestinal Gel
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours.
Trial: NCT01736176
Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
Trial: NCT00782535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled solution, single dose of placebo
Trial: NCT00781768
Drug: Standard PO (Zofran + Dexamethason)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
Trial: NCT02447393
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02466815
Drug: JNJ-42756493 Current Clinical Formulation (G-018)
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
Trial: NCT03055806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo caplet(s)
Trial: NCT00125138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup formulation
Trial: NCT02630459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo via subcutaneous injection
Trial: NCT06300866
Drug: Test
RxNorm normalized name: Testro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: test toothpaste containing 0.45% stannous fluoride
Trial: NCT02114359
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 1000mg/m2 po bid)
Trial: NCT00966654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
Trial: NCT02466815
Drug: JNJ-42756493 Prototype Formulation I (G-025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
Trial: NCT02466815
Drug: JNJ-42756493 Prototype Formulation II (G-025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
Trial: NCT02156843
Drug: Pyridorin
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.
Trial: NCT02156843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
Trial: NCT00005838
Drug: shark cartilage extract AE-941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02058186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03520842
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00117520
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00336960
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
Trial: NCT00274105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00336960
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive concurrent fluorouracil IV continuously for 5 weeks.
Trial: NCT03770234
Drug: Transtec 35 µg/hour transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
Trial: NCT00747903
Drug: aminolevulinic acid hydrochloride
RxNorm normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01241643
Drug: CYT107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
Trial: NCT02182505
Drug: Berodual® Respimat®, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03184805
Drug: Stopping aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
Trial: NCT00366106
Drug: doxorubicin HCl liposome
RxNorm normalized name: DOXORUBICIN HCL LIPOSOME 2MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m\^2 on Day 4 every 28 days (cycle).
Trial: NCT00139152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline, Sub-Cuteanous (SQ)
Trial: NCT02490436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized cross-over between cetuximab and placebo
Trial: NCT03720067
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg / day
Trial: NCT03203525
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via pump
Trial: NCT03203525
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via pump
Trial: NCT03203525
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06239155
Drug: AST-3424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid formulation for Intravenous infusion
Trial: NCT04094038
Drug: Glucose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 5%
Trial: NCT00993694
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03070262
Drug: placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet, 3 tablets, tid, po
Trial: NCT02891174
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with ibuprofen followed by acetaminophen.